Racura Oncology Ltd (ASX: RAC) - Share Price
Current share price for RAC : $2.250 0.03 (1.35%)+
Racura Oncology (RAC), an ASX-listed company, is a Phase 3 clinical biopharmaceutical company with a mission to be at the heart of cancer care.
RAC General Information +
| ASX Code | RAC |
| Website | http://www.racuraoncology.com |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 441 |
| RAC Share Price | $2.250 |
| Day High | $2.280 |
| Day Low | $2.200 |
| Last Close | $2.220 |
| RAC Share Price Movement | $0.03 ( 1.35% ) |
Prices as at 11:55, 1 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Racura Oncology Ltd (RAC) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Racura Oncology Ltd (RAC) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Racura Oncology Ltd (RAC) price-sensitive announcements
RAC - Racura Treats First Patient in HARNESS-1 Lung Cancer Trial
Racura Oncology Ltd has announced the treatment of the first patient in the HARNESS-1 Phas
Racura Oncology Ltd (RAC)
25 Jun 2026 | 8:55 AM
25 Jun 2026 | 8:55 AM
RAC - Racura raised $34.3m to Advance Three Oncology Trials
Racura Oncology Ltd has successfully raised $34.3 million from both Bonus and Piggyback Op
Racura Oncology Ltd (RAC)
16 Jun 2026 | 12:36 PM
16 Jun 2026 | 12:36 PM
RAC - Emerging Companies Specialist Invests in Racura
Racura Oncology Ltd has secured funding from a specialist institutional investor through a
Racura Oncology Ltd (RAC)
4 Jun 2026 | 8:50 AM
4 Jun 2026 | 8:50 AM
RAC - Racura Enters Underwriting Agreement for Options
Racura Oncology Ltd has entered into an Underwriting Agreement with Dr AJ Robinson to unde
Racura Oncology Ltd (RAC)
28 May 2026 | 4:43 PM
28 May 2026 | 4:43 PM
Racura Oncology Ltd (RAC) Recent ASX Announcements
RAC Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$4.79 | -$2.80 | -66.90% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$13.82 | -$8.40 | 36.10% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$9.92 | -$6.20 | -15.60% | 0.00 | 0.00 | 0.00% | 0.0% |
RAC Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| CSL Limited (CSL) | $55,262M | 0.1108 | -0.1276 | 0.0166 | 12.3733 | 14.1835 | 13.9517 | 3.86% | 3.13% | 3.26% |
| Clinuvel Pharmaceuticals Limited (CUV) | $522M | 0.0287 | -0.0028 | 0.1257 | 14.4150 | 14.4553 | 12.8412 | 0.48% | 0.68% | 1.49% |
| Mesoblast Limited (MSB) | $2,524M | 0.0301 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Racura Oncology Ltd (RAC) | $437M | -0.6690 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $5,488M | -1.3893 | 0.0000 | -0.1299 | 0.0000 | 300.0000 | 344.7761 | 0.00% | 0.00% | 0.00% |
RAC Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 24.10 | 0.00 |
| Market | 0.29 | 13.30 | 1.15 | 0.69 |
| Sector | 0.43 | 26.00 | 2.47 | 1.93 |
RAC Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Daniel Tillett | Chief Executive Officer, Managing Director | 1 Sep 2024 |
| Dr Peter (Pete) Smith | Executive Director, Executive Chairman | 28 Jun 2023 |
| Dr Megan Baldwin | Non-Executive Director | 1 Jan 2025 |
| Dr Serge Scrofani | Non-Executive Director | 1 Sep 2024 |
Racura Oncology Ltd (RAC) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 5 Jun 2026 | SCROFANI, Serge | Buy | Indirect Shares | 11,285 | $2.692 | $30,375.290 |
| 28 May 2026 | TILLETT, Daniel | Exercise | Options | 400,000 | $1.250 | $500,000.000 |
| 28 May 2026 | TILLETT, Daniel | Buy | Direct Shares | 400,000 | $1.250 | $500,000.000 |
See all changes in directors' interest & trades for Racura Oncology Ltd (RAC) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
RAC Management
| Name | Position |
|---|---|
| Peter Webse | Company Secretary |
RAC Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Racura Oncology Ltd (RAC). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 17,267,615 (9.94%) | Daniel Tillett |
RAC Calendar of Events
| Date | Event |
|---|---|
| 26 February 2027 | Report (Interim) |
| 25 August 2026 | Report (Annual) |
| 25 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
